TIDE scores, a new scoring system that integrates T-cell dysfunction and cell rejection markers to simulate tumor immune escape, can predict ICB response rates and have been shown to be superior to PD-L1 and TMB in predicting the immunotherapy responses of malignant melanoma (Jiang et al., 2018). The gene discussed is CD274; the disease is melanoma.